Brain Glucose Metabolism in Cerebral Amyloid Angiopathy: An FDG-PET Study.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 23 2 2021
medline: 15 12 2021
entrez: 22 2 2021
Statut: ppublish

Résumé

The in vivo diagnosis of cerebral amyloid angiopathy (CAA) is currently based on the Boston criteria, which largely rely on hemorrhagic features on brain magnetic resonance imaging. Adding to these criteria From a large memory clinic database, we retrospectively included all patients in whom both brain magnetic resonance imaging and FDG positron emission tomography had been obtained as part of routine clinical care and who fulfilled the Boston criteria for probable CAA. None had a history of symptomatic intracerebral hemorrhage. FDG data processing involved (1) spatial normalization to the Montreal Neurology Institute/International Consortium for Brain Mapping 152 space and (2) generation of standardized FDG uptake (relative standardized uptake value; relative to the pons). The relative standardized uptake value data obtained in 13 regions of interest sampling key cortical areas and the cerebellum were compared between the CAA and age-matched control groups using 2 separate healthy subject databases and image-processing pipelines. The presence of significant hypometabolism (2-tailed Fourteen patients fulfilling the Boston criteria for probable CAA (≥2 exclusively lobar microbleeds) were identified. Significant hypometabolism ( Supporting our hypothesis, significant glucose hypometabolism predominantly affected posterior cortical regions, including the visual cortex. These findings from a small sample may have diagnostic implications but require replication in larger prospective studies. In addition, whether they generalize to CAA-related symptomatic intracerebral hemorrhage warrants specific studies.

Sections du résumé

BACKGROUND AND PURPOSE
The in vivo diagnosis of cerebral amyloid angiopathy (CAA) is currently based on the Boston criteria, which largely rely on hemorrhagic features on brain magnetic resonance imaging. Adding to these criteria
METHODS
From a large memory clinic database, we retrospectively included all patients in whom both brain magnetic resonance imaging and FDG positron emission tomography had been obtained as part of routine clinical care and who fulfilled the Boston criteria for probable CAA. None had a history of symptomatic intracerebral hemorrhage. FDG data processing involved (1) spatial normalization to the Montreal Neurology Institute/International Consortium for Brain Mapping 152 space and (2) generation of standardized FDG uptake (relative standardized uptake value; relative to the pons). The relative standardized uptake value data obtained in 13 regions of interest sampling key cortical areas and the cerebellum were compared between the CAA and age-matched control groups using 2 separate healthy subject databases and image-processing pipelines. The presence of significant hypometabolism (2-tailed
RESULTS
Fourteen patients fulfilling the Boston criteria for probable CAA (≥2 exclusively lobar microbleeds) were identified. Significant hypometabolism (
CONCLUSIONS
Supporting our hypothesis, significant glucose hypometabolism predominantly affected posterior cortical regions, including the visual cortex. These findings from a small sample may have diagnostic implications but require replication in larger prospective studies. In addition, whether they generalize to CAA-related symptomatic intracerebral hemorrhage warrants specific studies.

Identifiants

pubmed: 33611942
doi: 10.1161/STROKEAHA.120.032905
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1478-1482

Auteurs

Sébastien Bergeret (S)

Department of Nuclear Medicine, CHU de Martinique, Université des Antilles, Fort-de-France (S.B., K.F.).

Mathieu Queneau (M)

Department of Nuclear Medicine (M.Q.), Centre Cardiologique du Nord, Saint-Denis, France.

Mathieu Rodallec (M)

Department of Radiology (M.R.), Centre Cardiologique du Nord, Saint-Denis, France.

Brigitte Landeau (B)

INSERM U1237, Université Caen Normandie, France (G.C., B.L.).
CYCERON Biomedical Imaging Platform, Caen, France (G.C., B.L.).

Gaël Chetelat (G)

INSERM U1237, Université Caen Normandie, France (G.C., B.L.).
CYCERON Biomedical Imaging Platform, Caen, France (G.C., B.L.).

Young T Hong (YT)

Department of Clinical Neurosciences, Wolfson Brain Imaging Centre, University of Cambridge, United Kingdom (Y.T.H.).

Julien Dumurgier (J)

INSERM U1144 (J.D., J.H., C.P., K.F.), Université de Paris, France.

Jacques Hugon (J)

INSERM U1144 (J.D., J.H., C.P., K.F.), Université de Paris, France.
Assistance Publique-Hopitaux de Paris, Cognitive Neurology Center, Saint-Louis-Lariboisière-Fernand-Widal Hospital Group, Paris, France (J.H., C.P.).

Claire Paquet (C)

INSERM U1144 (J.D., J.H., C.P., K.F.), Université de Paris, France.
Assistance Publique-Hopitaux de Paris, Cognitive Neurology Center, Saint-Louis-Lariboisière-Fernand-Widal Hospital Group, Paris, France (J.H., C.P.).

Karim Farid (K)

Department of Nuclear Medicine, CHU de Martinique, Université des Antilles, Fort-de-France (S.B., K.F.).
INSERM U1144 (J.D., J.H., C.P., K.F.), Université de Paris, France.

Jean-Claude Baron (JC)

Department of Neurology, Sainte-Anne Hospital (J.-C.B.), Université de Paris, France.
INSERM U1266 (J.-C.B.), Université de Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH